The state of Connecticut currently has 9 active clinical trials seeking participants for Parkinson's Disease research studies. These trials are conducted in various cities, including New Haven, Hartford, Farmington and Stamford.
A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
NCT06680830
Recruiting
The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway. Participants will: • Take NEU-411 or placebo every day for 52 weeks
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
08/18/2025
Locations: Invicro, New Haven, Connecticut
Conditions: Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
Register for Updates
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
NCT06976268
Recruiting
A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
08/18/2025
Locations: Site-028, New Haven, Connecticut
Conditions: Parkinson Disease
Register for Updates
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
NCT04477785
Recruiting
The Parkinson Progression Marker Initiative (PPMI) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls. The overall goal of PPMI is to identify markers of disease progression for use in clinical trials of therapies to reduce progression of PD disability.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
07/15/2025
Locations: Institute For Neurodegenerative Disorders, New Haven, Connecticut
Conditions: Parkinson Disease
Register for Updates
Imaging Depression in Parkinson's Disease
NCT06402955
Recruiting
The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/09/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Parkinson's Disease, Major Depressive Disorder
Register for Updates
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
NCT07020026
Recruiting
The study aims to evaluate the burden of tau pathology in people with Sporadic and LRRK2 PD via in vivo imaging using the tau tracer, \[18F\]PI-2620, and a high resolution PET camera, NeuroEXPLORER.
Gender:
ALL
Ages:
Between 45 years and 85 years
Trial Updated:
06/05/2025
Locations: Institute for Neurodegenerative Disorders / XingImaging, LLC, New Haven, Connecticut
Conditions: Parkinson's Disease
Register for Updates
Neurologic Stem Cell Treatment Study
NCT02795052
Recruiting
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: MD Stem Cells, Westport, Connecticut
Conditions: Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Register for Updates
Parkinson's Foundation PD GENEration Genetic Registry
NCT04994015
Recruiting
Development of a central repository for PD-related genomic data for future research.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2025
Locations: Hartford Healthcare, Hartford, Connecticut
Conditions: Parkinson's Disease
Register for Updates
Ketamine for the Treatment of Depression in Parkinson's Disease
NCT04944017
Recruiting
The main purpose of this study is to examine the efficacy and safety of a repeated dosing ketamine infusion paradigm compared to placebo in individuals with PD. A subset of participants in each arm will undergo baseline and post-treatment PET and fMRI scans, to examine whether changes in synaptic density and reorganization of functional networks underlie ketamine's putative antidepressant effects in PD.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
11/08/2024
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Parkinson's Disease, Depression
Register for Updates
Intestinal Immunity in Neurologic Disease
NCT06329453
Recruiting
The purpose of this study is to ascertain the functional profiles of the immune cells within the gastrointestinal tract and to determine how these cells contribute to autoimmune and neurologic diseases.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/22/2024
Locations: Yale MS Clinic, North Haven, Connecticut
Conditions: Multiple Sclerosis, Parkinson Disease, REM Sleep Behavior Disorder
Register for Updates